Nanjing Vazyme Biotech Co., Ltd (SHA:688105)
China · Delayed Price · Currency is CNY 19.50
-0.12 (-0.61%)
Sep 11, 2026, 3:00 PM CST
Nanjing Vazyme Biotech Revenue
Nanjing Vazyme Biotech had revenue of 379.80M CNY in the quarter ending June 30, 2026, with 18.23% growth. This brings the company's revenue in the last twelve months to 1.47B, up 10.28% year-over-year. In the year 2025, Nanjing Vazyme Biotech had annual revenue of 1.38B.
Revenue (ttm)
1.47B
Revenue Growth
+10.28%
P/S Ratio
6.85
Revenue / Employee
490.38K
Employees
3,002
Market Cap
10.08B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.38B | -16.98K | - |
| Dec 31, 2024 | 1.38B | 91.91M | 7.15% |
| Dec 31, 2023 | 1.29B | -2.28B | -63.97% |
| Dec 31, 2022 | 3.57B | 1.70B | 90.99% |
| Dec 31, 2021 | 1.87B | 304.17M | 19.44% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Chengzhi | 11.19B |
| Pacific Shuanglin Bio-pharmacy | 2.48B |
| Tibet Cheezheng Tibetan Medicine | 2.22B |
| Inner Mongolia Furui Medical Science | 1.64B |
| Jiangxi Fushine Pharmaceutical | 1.56B |
| Hualan Biological Vaccine | 1.19B |
| Mabwell (Shanghai) Bioscience | 873.99M |
| Chengdu Olymvax Biopharmaceuticals | 759.63M |